Morgan Stanley raised the firm’s price target on Donaldson (DCI) to $69 from $65 and keeps an Underweight rating on the shares. The firm updated estimates and is rolling forward its valuation to FY26 and increasing share repurchase expectations, but remains Underweight following fiscal Q3 reporting as it continues to see risk to the Life Sciences growth strategy, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCI:
- Hold Rating on Donaldson Company Amid Bioprocessing Challenges and Market Uncertainties
- Donaldson price target raised to $78 from $76 at Baird
- Donaldson’s Business at Risk: How International Tariffs Could Impact Operations and Competitiveness
- Morning Movers: Signet Jewelers and Dollar General surge following Q1 results
- Donaldson Company Appoints New COO Amidst Strong Q3 Results